New program aims to make HIV injections easier for women facing homelessness or food insecurity

NCT ID NCT06411223

Ongoing Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a pharmacist-led program to help women with HIV who also face social challenges like housing or food insecurity. The program supports switching from daily pills to a long-acting injectable medication (cabotegravir/rilpivirine) given every two months. The goal is to see if this approach is practical and acceptable for these women.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabotegravir/Rilpivirine (long-acting injectable HIV medication)
What this could lead to: If successful, this could show that a pharmacist-led support program helps women with social challenges stick with long-acting HIV treatment, improving their health.
What could go wrong: This is a small early-phase study (50 people) focused on feasibility, not on proving the treatment works. Results may not apply to all women or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Yale Clinical and Community Research

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.